IL239714A0 - Combination of glp1r agonist and metformin and its use in the treatment of type 2 diabetes and other diseases - Google Patents
Combination of glp1r agonist and metformin and its use in the treatment of type 2 diabetes and other diseasesInfo
- Publication number
- IL239714A0 IL239714A0 IL239714A IL23971415A IL239714A0 IL 239714 A0 IL239714 A0 IL 239714A0 IL 239714 A IL239714 A IL 239714A IL 23971415 A IL23971415 A IL 23971415A IL 239714 A0 IL239714 A0 IL 239714A0
- Authority
- IL
- Israel
- Prior art keywords
- metformin
- diabetes
- disorders
- combinations
- treatment
- Prior art date
Links
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 title 1
- 229960003105 metformin Drugs 0.000 title 1
- GNZCSGYHILBXLL-UHFFFAOYSA-N n-tert-butyl-6,7-dichloro-3-methylsulfonylquinoxalin-2-amine Chemical compound ClC1=C(Cl)C=C2N=C(S(C)(=O)=O)C(NC(C)(C)C)=NC2=C1 GNZCSGYHILBXLL-UHFFFAOYSA-N 0.000 title 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/24—Y being a hetero atom
- C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361753567P | 2013-01-17 | 2013-01-17 | |
| PCT/US2014/011394 WO2014113357A1 (en) | 2013-01-17 | 2014-01-14 | Combinations of a glp1r agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL239714A0 true IL239714A0 (en) | 2015-08-31 |
Family
ID=50030537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL239714A IL239714A0 (en) | 2013-01-17 | 2015-06-30 | Combination of glp1r agonist and metformin and its use in the treatment of type 2 diabetes and other diseases |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20150313908A1 (enExample) |
| EP (1) | EP2945618B1 (enExample) |
| JP (1) | JP6445459B2 (enExample) |
| KR (1) | KR102165434B1 (enExample) |
| CN (1) | CN104968341B (enExample) |
| AU (1) | AU2014207748B2 (enExample) |
| CA (1) | CA2896308C (enExample) |
| EA (1) | EA201591123A1 (enExample) |
| ES (1) | ES2687083T3 (enExample) |
| IL (1) | IL239714A0 (enExample) |
| MX (1) | MX366685B (enExample) |
| SG (2) | SG10201704716XA (enExample) |
| WO (1) | WO2014113357A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019060653A1 (en) | 2017-09-22 | 2019-03-28 | Regeneron Pharmaceuticals, Inc. | GLP-1 RECEPTOR AGONISTS (GLUCAGON-LIKE PEPTIDE 1) AND USES THEREOF |
| CA3090823A1 (en) * | 2018-05-08 | 2019-11-14 | Vtv Therapeutics Llc | Therapeutic uses of glp1r agonists |
| CN115461344B (zh) * | 2020-04-01 | 2024-01-12 | 杭州中美华东制药有限公司 | 一种glp-1受体激动剂的晶型a及其制备方法 |
| WO2021196951A1 (zh) * | 2020-04-01 | 2021-10-07 | 杭州中美华东制药有限公司 | Glp-1受体激动剂游离碱的药学上可接受的酸式盐及其制备方法 |
| EP4272733A4 (en) * | 2020-12-31 | 2024-07-10 | Dong Kook Pharm. Co., Ltd | PHARMACEUTICAL COMPOSITION CONTAINING TADALAFIL OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND DUTASTERIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF HAVING A NOVEL DISSOLUTION RATE |
| WO2024064842A1 (en) | 2022-09-21 | 2024-03-28 | Regeneron Pharmaceuticals, Inc. | Methods of treating obesity, diabetes, and liver dysfunction |
| WO2025158275A1 (en) | 2024-01-24 | 2025-07-31 | Pfizer Inc. | Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4080472A (en) | 1974-03-22 | 1978-03-21 | Societe D'etudes Et D'exploitation De Marques Et Brevets S.E.M.S. | Metformin 2-(p-chlorophenoxy)-2-methylpropionate |
| JP2009514896A (ja) * | 2005-11-07 | 2009-04-09 | エリクシアー ファーマシューティカルズ， インコーポレイテッド | メトホルミンおよびメグリチニドの組み合わせ |
| WO2009111700A2 (en) * | 2008-03-07 | 2009-09-11 | Transtech Pharma, Inc. | Oxadiazoanthracene compounds for the treatment of diabetes |
| CN102378574B (zh) | 2009-03-30 | 2013-11-20 | 转化技术制药公司 | 取代的偶氮蒽衍生物、药物组合物及其使用方法 |
| WO2011031620A1 (en) | 2009-09-11 | 2011-03-17 | Transtech Pharma, Inc. | Solid compositions comprising an oxadiazoanthracene compound and methods of making and using the same |
| CA2780460C (en) * | 2009-11-13 | 2018-09-04 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine |
| US20110118180A1 (en) * | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to metformin |
| US20130040878A1 (en) * | 2011-05-13 | 2013-02-14 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for use in the treatment of diabetes type 2 patients |
-
2014
- 2014-01-14 KR KR1020157018661A patent/KR102165434B1/ko active Active
- 2014-01-14 SG SG10201704716XA patent/SG10201704716XA/en unknown
- 2014-01-14 CA CA2896308A patent/CA2896308C/en active Active
- 2014-01-14 JP JP2015553775A patent/JP6445459B2/ja active Active
- 2014-01-14 AU AU2014207748A patent/AU2014207748B2/en active Active
- 2014-01-14 EA EA201591123A patent/EA201591123A1/ru unknown
- 2014-01-14 MX MX2015008555A patent/MX366685B/es active IP Right Grant
- 2014-01-14 SG SG11201504778UA patent/SG11201504778UA/en unknown
- 2014-01-14 ES ES14702159.6T patent/ES2687083T3/es active Active
- 2014-01-14 WO PCT/US2014/011394 patent/WO2014113357A1/en not_active Ceased
- 2014-01-14 EP EP14702159.6A patent/EP2945618B1/en active Active
- 2014-01-14 CN CN201480004613.0A patent/CN104968341B/zh active Active
-
2015
- 2015-06-30 IL IL239714A patent/IL239714A0/en unknown
- 2015-07-14 US US14/799,222 patent/US20150313908A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014113357A1 (en) | 2014-07-24 |
| JP2016505039A (ja) | 2016-02-18 |
| SG10201704716XA (en) | 2017-07-28 |
| CN104968341A (zh) | 2015-10-07 |
| AU2014207748A1 (en) | 2015-07-09 |
| JP6445459B2 (ja) | 2018-12-26 |
| CN104968341B (zh) | 2020-06-09 |
| EA201591123A1 (ru) | 2015-11-30 |
| EP2945618B1 (en) | 2018-06-13 |
| SG11201504778UA (en) | 2015-07-30 |
| MX366685B (es) | 2019-07-19 |
| CA2896308C (en) | 2021-11-09 |
| AU2014207748B2 (en) | 2018-10-11 |
| KR20150104572A (ko) | 2015-09-15 |
| ES2687083T3 (es) | 2018-10-23 |
| MX2015008555A (es) | 2016-01-22 |
| CA2896308A1 (en) | 2014-07-24 |
| KR102165434B1 (ko) | 2020-10-14 |
| HK1210424A1 (en) | 2016-04-22 |
| EP2945618A1 (en) | 2015-11-25 |
| US20150313908A1 (en) | 2015-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL269661B (en) | 3,1-thiazol-2-yl converted benzamides | |
| IL245408A0 (en) | Converted benzamides for the treatment of arthropods | |
| IL240285A0 (en) | Biomarkers for type ii diabetes and their uses | |
| PT2919796T (pt) | Utilização de akkermansia para o tratamento de distúrbios metabólicos | |
| PL3811943T3 (pl) | Związek do stosowania w leczeniu zaburzeń oczu | |
| PL3046470T3 (pl) | Diagnozowanie i leczenie zaburzeń ruchu | |
| IL239714A0 (en) | Combination of glp1r agonist and metformin and its use in the treatment of type 2 diabetes and other diseases | |
| PL2968218T3 (pl) | Skojarzenie do leczenia choroby parkinsona | |
| IL239957A0 (en) | Assessment, testing and treatment of pkal mediated disorders | |
| IL238027A0 (en) | 2-phenyl-5-heterocyclyl-tetrahydro-h2-pyran-3-amine compounds for use in the treatment of diabetes and related disorders | |
| IL243572A0 (en) | Drug combination for the treatment of melanoma | |
| GB2519982B (en) | Fungicidal composition and the use thereof | |
| IL242437B (en) | Compound 9, 5-dimethyl-9-hydroxy-decan-4-al, its use and its preparation process | |
| PL3041441T3 (pl) | Orteza ręki do podtrzymywania kciuka szczególnie w przypadku rizartrozy | |
| HUE039750T2 (hu) | Hidroxi-buspiron mozgászavarok kezelésére | |
| IL241474B (en) | A device with joints for the wrist | |
| PT3074033T (pt) | Compostos para o tratamento de obesidade e métodos de utilização dos mesmos | |
| GB201320506D0 (en) | Cyclic amino compounds for the use in the treatment of cardiac disorders | |
| EP3713604C0 (de) | Verbindung zur anwendung bei der steigerung von mentaler leistungsfähigkeit | |
| GB201800645D0 (en) | Monitoring medication consumption | |
| GB201314183D0 (en) | Status of type 2 diabetes | |
| GB201304197D0 (en) | Thumb pad embodiments | |
| TWM476976U (en) | Wrist pad | |
| TWM476582U (en) | Watch type stethoscope device | |
| GB201320349D0 (en) | New therapeutic use |